Mucosal Repair and COX-2 Inhibition
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2207-2211
Author(s):
Rafael F. Perini, Li Ma and John L. Wallace
COX-2 Inhibition, H. pylori Infection and the Risk of Gastrointestinal Complications
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2213-2219
Author(s):
Francis K.L. Chan
COX-2 Inhibition Versus Gastroprotection with Dual COX Inhibitors: An Evidence-Based Approach
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2221-2228
Author(s):
Alexander J.V. Thompson and Neville D. Yeomans
COX-2 and Colorectal Cancer
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2229-2251
Author(s):
A. Ferrandez, S. Prescott and R. W. Burt
Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2253-2266
Author(s):
Angel Lanas, Julian Panes and Josep M. Pique
COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2267-2280
Author(s):
E. Piazuelo, P. Jimenez and A. Lanas
Cyclooxygenase-2 Inhibition and Gastric Cancer
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2281-2288
Author(s):
Xiao Hua Jiang and C. Y. Wong
Structure and Functional Relationships of Hsp90
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
301-323
Author(s):
Chrisostomos Prodromou and Laurence H. Pearl
The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
349-358
Author(s):
Luke Whitesell, Rochelle Bagatell and Ryan Falsey
Crystallization And Preliminary X-Ray Diffraction Analysis Of Phosphoglucose Isomerase From Pyrococcus Furiosus
Journal:
Protein & Peptide Letters
Volume:
10
Page:
517-520
Author(s):
Michael K. Swan, Thomas Hansen, Peter Schonheit and Christopher Davies